Use of Danazol Alone with Danazol Combined with Evening Primrose Oil for the Treatment of Fibrocystic Breast Disease A Comparative study of 200 cases

In: TAJ: Journal of Teachers Association · 2024 · vol. 37(2) · doi:10.70818/taj.v37i2.0118 · W4408185760
article OA: diamond CC0

Abstract

Background: Fibrocystic breast disease, also known as mammary dysplasia, is a non-cancerous condition that results in breast lumps, pain, and discomfort.Objective: This study aims to compare the effectiveness of Danazol alone versus Danazol combined with Evening Primrose Oil (EP) in treating fibrocystic breast disease.Method: A randomized controlled study was conducted on 200 outpatients at Chuadanga Sadar Hospital, Bangladesh, from January 2022 to December 2023.Patients were divided into two groups.Group A received Evening Primrose Oil 1000 mg twice daily combined with Danazol 100 mg twice daily for three months.Group B Danazol 100 mg twice daily alone for three months.Pain levels were compared using mean and standard deviation, and an independent sample T-test was employed.The efficacy of the treatments was further analyzed using the chi-square test.Results: The study included 200 patients with a mean age of 30.54 4.53 years.The VAS pain score between the two groups showed a mean difference of 1.530.27.The results indicated significantly lower pain in the group using Danazol combined with EP capsules compared to Danazol alone (p = 0.001).The percentage of response in Group B was higher than in Group A. Conclusion: Danazol combined with Evening Primrose Oil is more effective in reducing pain in patients with fibrocystic breast disease compared to Danazol alone.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-05-14T06:31:37.849631+00:00
License: CC0 · commercial use OK